Executive Insights from the 2026 AWS Life Sciences Symposium

This article recaps the 2026 AWS Life Sciences Symposium keynote, exploring how life sciences organizations can successfully scale AI from proof-of-concept to production.

• Only 22% of life sciences leaders report successfully scaling AI, yet some companies advance AI-assisted drug candidates to late-stage trials
• Success requires building for production from day one, not scaling from PoCs later
• Eli Lilly's Cortex platform standardizes AI guardrails across 52+ models and 60+ enterprise applications globally
• Organizations must adopt a "builder mentality" empowering all employees with AI tools and domain expertise
• Semantic data layers help agents understand industry-specific ontologies, taxonomies, and relationships
• Amazon Bedrock AgentCore and Amazon Quick enable teams to build and deploy agents at scale
• AWS announced Amazon Bio Discovery, an AI application automating drug design and wet-lab validation
• Success requires decision environments integrating science, behavioral insight, and trusted technology foundations

Life sciences organizations achieving AI impact share common traits: building for production, empowering employee innovation, and leveraging technology as a catalyst for real-world outcomes.